| Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
|
Blood cells, molecules and diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat |
|
Journal for immunotherapy of cancer |
Myelodysplastic Syndromes (MDS) |
| Detectable mutations precede late myeloid neoplasia in aplastic anemia |
|
Haematologica |
Aplastic Anemia |
| Luspatercept in the treatment of lower-risk myelodysplastic syndromes |
|
Future Oncology (London, England) |
Myelodysplastic Syndromes (MDS) |
| Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options |
|
Cancer Management and Research |
Myelodysplastic Syndromes (MDS) |
| Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria |
|
Leukemia |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
